Andrea Ibarra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andrea Ibarra has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Arvind Shakya
University of Utah School of Medicine
1 shared publication - Brian D. Evavold
Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA
1 shared publication - Cody N. German
University of Utah School of Medicine
1 shared publication - Danny Hung-Chieh Chou
Stanford University
1 shared publication - Dean Tantin
University of Utah School of Medicine
1 shared publication - Heejoo Kim
University of Utah School of Medicine
1 shared publication
Latest Publications
- Open Access
- 7 February 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Targeting transcriptional coregulator OCA-B/Pou2af1 blocks activated autoreactive T cells in the pancreas and type-1 diabetes
The transcriptional coregulator OCA-B promotes expression of T cell target genes in cases of repeated antigen exposure, a necessary feature of autoimmunity. We hypothesized that T cell-specific OCA-B deletion and pharmacologic OCA-B inhibition would protect mice from autoimmune diabetes. We developed anOcabconditional allele and backcrossed it onto a diabetes-prone NOD/ShiLtJ strain background. T cell-specific OCA-B loss protected mice from spontaneous disease. Protection was associated with large reductions in islet CD8+T cell receptor specificities associated with diabetes pathogenesis. CD4+clones associated with diabetes were present, but associated with anergic phenotypes. The protective effect of OCA-B loss was recapitulated using autoantigen-specific NY8.3 mice, but diminished in monoclonal models specific to artificial or neoantigens. Rationally-designed membrane-penetrating OCA-B peptide inhibitors normalized glucose levels, and reduced T cell infiltration and proinflammatory cytokine expression in newly-diabetic NOD mice. Together, the results indicate that OCA-B is a potent autoimmune regulator and a promising target for pharmacologic inhibition.~40-word summary statement for the online JEM table of contents and alerts: Kim and colleagues show that OCA-B in T cells is essential for the generation of type-1 diabetes. OCA-B loss leaves the pancreatic lymph nodes largely undisturbed, but associates autoreactive CD4+T cells in the pancreas with anergy while deleting potentially autoreactive CD8+T cells.Summary: Kim et al. show that loss or inhibition of OCA-B in T cells protects mice from type-1 diabetes.
- 7 February 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Open AccessTargeting transcriptional coregulator OCA-B/Pou2af1 blocks activated autoreactive T cells in the pancreas and type-1 diabetes
The transcriptional coregulator OCA-B promotes expression of T cell target genes in cases of repeated antigen exposure, a necessary feature of autoimmunity. We hypothesized that T cell-specific OCA-B deletion and pharmacologic OCA-B inhibition would protect mice from autoimmune diabetes. We developed anOcabconditional allele and backcrossed it onto a diabetes-prone NOD/ShiLtJ strain background. T cell-specific OCA-B loss protected mice from spontaneous disease. Protection was associated with large reductions in islet CD8+T cell receptor specificities associated with diabetes pathogenesis. CD4+clones associated with diabetes were present, but associated with anergic phenotypes. The protective effect of OCA-B loss was recapitulated using autoantigen-specific NY8.3 mice, but diminished in monoclonal models specific to artificial or neoantigens. Rationally-designed membrane-penetrating OCA-B peptide inhibitors normalized glucose levels, and reduced T cell infiltration and proinflammatory cytokine expression in newly-diabetic NOD mice. Together, the results indicate that OCA-B is a potent autoimmune regulator and a promising target for pharmacologic inhibition.~40-word summary statement for the online JEM table of contents and alerts: Kim and colleagues show that OCA-B in T cells is essential for the generation of type-1 diabetes. OCA-B loss leaves the pancreatic lymph nodes largely undisturbed, but associates autoreactive CD4+T cells in the pancreas with anergy while deleting potentially autoreactive CD8+T cells.Summary: Kim et al. show that loss or inhibition of OCA-B in T cells protects mice from type-1 diabetes.